Norway's Bionor Pharma and U.K. scientists claim they've identified a biomarker in some patients that may be connected with an improved response to a therapeutic HIV vaccine now under development.
Celgene has agreed to help fund a study of its blockbuster blood-cancer drug Revlimid in HIV patients. Bionor Pharma, a Norwegian biotech focused on HIV, revealed plans on Monday to test a cocktail consisting of its experimental HIV treatment and Revlimid in Germany.
Norway's Bionor Pharma got a big boost out of the news that its HIV vaccine performed well in a new Phase IIb study, knocking down the virus by 64% when combined with an antiretroviral treatment. Its
Norway's Bionor Pharma's stock almost quadrupled on the news that its HIV vaccine Vacc-4x unexpectedly reduced viral load. The trial was designed to test HIV-patients' ability to stay off